Iceland’s #1 Dating App, Smitten, Raises $10M Series A From Makers Fund, Possible Ventures and More to Woo Gen Z-ers Globally With Its Fresh Approach to Dating
15.9.2022 14:01:00 EEST | Business Wire | Press release
Dating app Smitten has raised a $10M Series A from Makers Fund, Possible Ventures, Wonder Invest and current shareholders ByFounders, ProFounders, Tennin, and Smitten's board member and Vivino founder Heini Zachariassen. Smitten, the most popular dating app in Iceland and the second most popular in Denmark, will use the financing to grow its team and to expand to new markets as they woo Gen Zers with their fresh, gamified approach to dating.
“My co-founder, Asgeir, and I share an intense interest in how people connect and communicate,” says David Simonarson, Smitten Co-Founder and CEO. “After years of creating social consumer apps, we fell in love with the online dating space and launched Smitten in 2020. We created personality-based games and fun interactive profiles to make it easy for strangers to form meaningful connections. Seeing how much our users love Smitten, we believe we can become the leading player in online dating for Generation Z.”
Smitten is founded by David Simonarson, CEO, and Asgeir Visir, Designer, and was released by the founders and its CTO, Magnus Olafsson. Smitten mixes games, entertainment, and flirting to jumpstart conversations and help users engage more seamlessly. Smitten's fun and creative approach to dating has struck a chord with Gen Zers, proven by the app’s more than 200 million swipes to date and whopping 30%+ stickiness rate. Most dating apps leave people to convert a match into a conversation with awkward starts that lead nowhere. Smitten makes getting into a conversation as easy as swiping through use of games, interactive profiles and icebreakers. Smitten gets users into fun, quality conversations regardless of their conversation skills, and has found that more than 60% of Smitten matches result in a post-match interaction vs 11% on industry-leading app, Tinder*.
The key to Smitten’s post-match interactions are mini-games people can play on each other’s profiles. “Our questionnaire game, Guessary, allows you to get to know the other person you are viewing by guessing how they answered a series of Yes-and-No questions,” explained Asgeir Visir, Smitten Co-Founder and Designer. “You could be answering questions like ‘Have they ever been arrested?’ or ‘Do they like pineapple on their pizza?’ and you would get immediate feedback if you answered correctly or not. Another fun game, Lie Detector, is inspired by the age-old social game Two Truths and Lie, where people add three statements about themselves to their profile, and you have one chance to spot the lie. These games are designed for users to get to know the person they are viewing before deciding if they want to like them or not. And the beautiful part is when you match with someone, the results of the games are posted in the chat and act as an icebreaker, making it so much easier to initiate a fun conversation.”
“Social discovery and gaming is an increasingly interesting intersection, and the team at Smitten have created an amazingly fun experience that truly strikes a chord with young adults,” said Alli Ottarson, Makers' lead on the deal. “Having spent time building a strong relationship with the founders David and Ásgeir, we have been privileged to a front row seat to follow Smitten´s success. We share a common vision for how the next generation will meet and interact, and we’re thrilled to be a part of the Smitten journey."
To learn more about Smitten, please visit smittendating.com.
ABOUT SMITTEN
Smitten is on a mission to make the most fun dating app in the world. Through creative, unique profile games and entertaining content, Smitten transforms how people view online dating. While operating at the intersection of dating, gaming, and entertainment, Smitten gives its users superpowers by making it as easy as swiping to get into a fun and meaningful conversation. Smitten outperforms the industry-leading dating app regarding post-match interactions, with more than 60% of matches progressing to some interaction. Smitten is founded in Iceland by co-founders David Orn Simonarson, CEO, and Asgeir Visir, UX Designer. The seasoned duo has been working together creating social apps to connect people for the past ten years. The team's mission is to create the most fun dating app in the world.
*per research at https://arxiv.org/abs/1607.01952
About Makers Fund
Makers Fund is a global interactive entertainment venture capital firm focused on early-stage investments. Makers is dedicated to furthering growth and innovation in the interactive entertainment industry. With more than 90 portfolio companies to date, Makers provides founders strategic value that is deeply catered to companies across the value chain in the industry. For more information, visit makersfund.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005317/en/
Contact information
Sibel Sunar
fortyseven communications for Smitten
makersfund@fortyseven.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom